DK3470400T3 - Krystallinske former af ozanimod og ozanimodhydrochlorid samtfremgangsmåder til fremstilling deraf - Google Patents
Krystallinske former af ozanimod og ozanimodhydrochlorid samtfremgangsmåder til fremstilling deraf Download PDFInfo
- Publication number
- DK3470400T3 DK3470400T3 DK17812728.8T DK17812728T DK3470400T3 DK 3470400 T3 DK3470400 T3 DK 3470400T3 DK 17812728 T DK17812728 T DK 17812728T DK 3470400 T3 DK3470400 T3 DK 3470400T3
- Authority
- DK
- Denmark
- Prior art keywords
- ozanimod
- processes
- preparation
- crystalline forms
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610416179 | 2016-06-14 | ||
| CN201610493910 | 2016-06-29 | ||
| PCT/CN2017/088314 WO2017215617A1 (zh) | 2016-06-14 | 2017-06-14 | 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3470400T3 true DK3470400T3 (da) | 2025-06-16 |
| DK3470400T5 DK3470400T5 (da) | 2025-06-30 |
Family
ID=60663299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17812728.8T DK3470400T5 (da) | 2016-06-14 | 2017-06-14 | Krystallinske former af ozanimod og ozanimodhydrochlorid samt fremgangsmåder til fremstilling deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11111223B2 (da) |
| EP (2) | EP4566676A3 (da) |
| CN (2) | CN114957157A (da) |
| DK (1) | DK3470400T5 (da) |
| ES (1) | ES3022204T3 (da) |
| FI (1) | FI3470400T3 (da) |
| HR (1) | HRP20250558T1 (da) |
| HU (1) | HUE072197T2 (da) |
| LT (1) | LT3470400T (da) |
| PL (1) | PL3470400T3 (da) |
| PT (1) | PT3470400T (da) |
| RS (1) | RS66905B1 (da) |
| SI (1) | SI3470400T1 (da) |
| SM (1) | SMT202500228T1 (da) |
| WO (1) | WO2017215617A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3470400T3 (pl) | 2016-06-14 | 2025-08-04 | Receptos Llc | Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania |
| CN109563059A (zh) | 2016-08-19 | 2019-04-02 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
| EP3508481A1 (en) | 2016-09-14 | 2019-07-10 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of ozanimod hydrochloride, and preparation method therefor |
| PT3630738T (pt) * | 2017-05-22 | 2023-10-24 | Egyt Gyogyszervegyeszeti Gyar | Processo para a produção de ozanimod |
| CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
| WO2019042219A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| CN107840830A (zh) * | 2017-09-20 | 2018-03-27 | 广东东阳光药业有限公司 | 盐酸奥扎莫德无水晶型i |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| WO2020152718A1 (en) * | 2019-01-25 | 2020-07-30 | Mylan Laboratories Limited | Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile |
| US12404256B2 (en) | 2019-07-16 | 2025-09-02 | Synthon B.V. | Process for preparing ozanimod |
| US12398112B2 (en) | 2020-04-02 | 2025-08-26 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| CN121194965A (zh) | 2023-05-31 | 2025-12-23 | 奎米卡新特缇卡股份有限公司 | 盐酸奥扎莫德的无定形形式和晶型 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2291080E (pt) | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| BRPI0912545B1 (pt) | 2008-05-14 | 2022-02-01 | The Scripps Research Institute | Compostos moduladores de receptores de esfingosina fosfato, uso dos mesmos e composição e combinação farmacêutica compreendendo os ditos compostos |
| PL2498610T5 (pl) | 2009-11-13 | 2024-11-04 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
| WO2015066515A1 (en) | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| US20180016244A1 (en) | 2015-04-06 | 2018-01-18 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| PL3470400T3 (pl) | 2016-06-14 | 2025-08-04 | Receptos Llc | Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania |
| CN109563059A (zh) | 2016-08-19 | 2019-04-02 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
| EP3508481A1 (en) | 2016-09-14 | 2019-07-10 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of ozanimod hydrochloride, and preparation method therefor |
| WO2018049632A1 (zh) | 2016-09-14 | 2018-03-22 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
| CN110612292A (zh) * | 2017-04-07 | 2019-12-24 | 杭州领业医药科技有限公司 | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 |
| WO2019042219A1 (zh) | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| CN107840830A (zh) | 2017-09-20 | 2018-03-27 | 广东东阳光药业有限公司 | 盐酸奥扎莫德无水晶型i |
-
2017
- 2017-06-14 PL PL17812728.8T patent/PL3470400T3/pl unknown
- 2017-06-14 PT PT178127288T patent/PT3470400T/pt unknown
- 2017-06-14 US US16/310,328 patent/US11111223B2/en active Active
- 2017-06-14 CN CN202210226424.4A patent/CN114957157A/zh active Pending
- 2017-06-14 DK DK17812728.8T patent/DK3470400T5/da active
- 2017-06-14 EP EP25155520.7A patent/EP4566676A3/en active Pending
- 2017-06-14 HU HUE17812728A patent/HUE072197T2/hu unknown
- 2017-06-14 LT LTEPPCT/CN2017/088314T patent/LT3470400T/lt unknown
- 2017-06-14 RS RS20250520A patent/RS66905B1/sr unknown
- 2017-06-14 SI SI201731601T patent/SI3470400T1/sl unknown
- 2017-06-14 HR HRP20250558TT patent/HRP20250558T1/hr unknown
- 2017-06-14 EP EP17812728.8A patent/EP3470400B1/en active Active
- 2017-06-14 ES ES17812728T patent/ES3022204T3/es active Active
- 2017-06-14 SM SM20250228T patent/SMT202500228T1/it unknown
- 2017-06-14 FI FIEP17812728.8T patent/FI3470400T3/fi active
- 2017-06-14 WO PCT/CN2017/088314 patent/WO2017215617A1/zh not_active Ceased
- 2017-06-14 CN CN201780029499.0A patent/CN109219597A/zh active Pending
-
2020
- 2020-01-21 US US16/748,303 patent/US11680050B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3470400A4 (en) | 2019-04-17 |
| WO2017215617A1 (zh) | 2017-12-21 |
| CN109219597A (zh) | 2019-01-15 |
| PL3470400T3 (pl) | 2025-08-04 |
| US11111223B2 (en) | 2021-09-07 |
| HRP20250558T1 (hr) | 2025-07-04 |
| RS66905B1 (sr) | 2025-07-31 |
| ES3022204T3 (en) | 2025-05-28 |
| US11680050B2 (en) | 2023-06-20 |
| CN114957157A (zh) | 2022-08-30 |
| LT3470400T (lt) | 2025-07-10 |
| EP3470400A1 (en) | 2019-04-17 |
| US20200157065A1 (en) | 2020-05-21 |
| SMT202500228T1 (it) | 2025-07-22 |
| PT3470400T (pt) | 2025-04-29 |
| DK3470400T5 (da) | 2025-06-30 |
| EP4566676A3 (en) | 2025-11-05 |
| SI3470400T1 (sl) | 2025-09-30 |
| HUE072197T2 (hu) | 2025-10-28 |
| FI3470400T3 (fi) | 2025-06-13 |
| US20190337908A1 (en) | 2019-11-07 |
| EP3470400B1 (en) | 2025-04-02 |
| EP4566676A2 (en) | 2025-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3470400T5 (da) | Krystallinske former af ozanimod og ozanimodhydrochlorid samt fremgangsmåder til fremstilling deraf | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3248967T3 (da) | Krystallinsk form af et benzimidazolderivat og en fremstillingsfremgangsmåde herfor | |
| DK3473621T3 (da) | Fremgangsmåde til fremstilling af diphenylmethan-derivat | |
| DK3294865T3 (da) | Fremgangsmåder til fremstilling af epimeraser og benzylisoquinolinalkaloider | |
| DK3519572T5 (da) | Forbindelser og fremgangsmåder til reduktion af tau-ekspression | |
| DK3484469T3 (da) | Sammensætninger og fremgangsmåder til potentiering af antimikrober | |
| DK3316748T3 (da) | Fremgangsmåde og indretning til fremstilling af en drikkevare | |
| DK3271347T3 (da) | Antifungale forbindelser og fremstillingsfremgangsmåder | |
| DK3515990T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3574135T3 (da) | Fremgangsmåde og formulering til fremstilling af ligninfibre | |
| DK3347342T3 (da) | Fremgangsmåde til fremstilling af biguanidin-salte og s-triaziner | |
| DK3215493T3 (da) | Syntese af copanlisib og dihydrochloridsalt deraf | |
| DK3412671T3 (da) | TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former | |
| DK3447051T3 (da) | Fremgangsmåde til fremstilling af tyrosinkinaseinhibitor og derivat deraf | |
| DK3665133T3 (da) | Fremgangsmåde og anlæg til fremstilling af cement | |
| DK3218351T3 (da) | Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377 | |
| PL3630738T3 (pl) | Sposób wytwarzania ozanimodu | |
| DK3323485T3 (da) | Krystalliseringssøjle og krystalliseringsfremgangsmåde | |
| DK3529236T3 (da) | Krystalformer af eravacyclin | |
| DK3516011T3 (da) | Fremgangsmåde til fremstilling af biokul og anlæg hertil | |
| DK3452424T3 (da) | Fremgangsmåde og anlæg til fremstilling af cement | |
| DK3331516T3 (da) | Hyperbar injektionsopløsning af ropivacainhydrochlorid og fremgangsmåde til fremstilling deraf | |
| DK3442944T3 (da) | Fremgangsmåde til fremstillingen af 4-aminoindanderivater og relaterede aminoindanamider |